Medivation, Pfizer deal

The companies partnered to develop and commercialize Medivation’s dimebon to treat Alzheimer’s disease (AD), Huntington’s disease and undisclosed indications. The small molecule that blocks an undisclosed target involving mitochondrial pores is in Phase III testing to treat AD and has completed Phase II testing to treat HD. Medivation will receive $225 million up front and is eligible for up to $500 million in development and regulatory milestones, plus undisclosed commercial milestones. ...